cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1497Research ArticleОБЗОРЫREVIEWSК вопросу о применении внутривенных β-адреноблокаторов у пациентов с острым коронарным синдромомIntravenous beta-adrenoblocker therapy in acute coronary syndrome patientsТерещенкоС. Н.TereshchenkoS. N.stereschenko@yandex.ruЖировИ. В.ZhirovI. V.stereschenko@yandex.ruГОУ ВПО Московский государственный медико-стоматологический университет Росздрава, МоскваMoscow State Medico-Stomatological University, State Federal Agency for Health and Social Development, Moscow200701011970779094Copyright © Терещенко С.Н., Жиров И.В., 19701970Терещенко С.Н., Жиров И.В.Tereshchenko S.N., Zhirov I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1497

Оптимизация лечения острого инфаркта миокарда (ОИМ) в ранние сроки позволяет улучшить клинические исходы, уменьшить заболеваемость и смертность у пациентов этой группы. Применение внутривенных β-адреноблокаторов (β-АБ) ассоциировано с улучшением выживаемости и хорошо переносится больными ОИМ. Представлены результаты клинических исследований по данному вопросу. Критически разобраны причины возможного повышения частоты кардиогенного шока у пациентов в группе метопролола в исследовании COMMIT. Дана доказательная база применения β-АБ в ранние сроки ОИМ.

Early treatment optimization improves clinical outcomes and reduces morbidity and mortality in patients with acute myocardial infarction (AMI). Intravenous beta-adrenoblocker (BAB) therapy, associated with improved survival, is well tolerated by AMI patients. The results of relevant clinical trials are presented. The causes of possible increase in cardiogenic shock risk for metoprolol group, COMMIT trial, are analyzed. Evidence base for early BAB therapy in AMI patients is presented.

острый инфаркт миокардаβ-адреноблокаторыкардиогенный шокгенетический полиморфизмacute myocardial infarctionbeta-adrenoblockerscardiogenic shockgenetic polymorphismReferencesThe Task Force on beta-blockers of the European Society of Cardiology. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004; 25; 1341-62.The Task Force on beta-blockers of the European Society of Cardiology. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004; 25; 1341-62.Явелов И.С. Применение бета-адреноблокаторов при сердечно-сосудистых заболеваниях: современные рекомендации. Cons Med 2005; 7; 945-56.Явелов И.С. Применение бета-адреноблокаторов при сердечно-сосудистых заболеваниях: современные рекомендации. Cons Med 2005; 7; 945-56.Yusuf S, Peto R, Lewis J, et al. Beta-blockade during and after myocardial infarction: an overview of the randomised trials. Prog Cardiovasc Dis 1985; 27: 335-71.Yusuf S, Peto R, Lewis J, et al. Beta-blockade during and after myocardial infarction: an overview of the randomised trials. Prog Cardiovasc Dis 1985; 27: 335-71.A Statement for healthcare professionals from the American Heart Association and the American College of Cardiology. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. Circulation 2001; 104: 1577-9.A Statement for healthcare professionals from the American Heart Association and the American College of Cardiology. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. Circulation 2001; 104: 1577-9.Third Joint Task Force of the European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-10.Third Joint Task Force of the European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-10.The MIAMI Trial Research Group: metoprolol in acute myocardial infarction (MIAMI). A randomised placebo controlled international trial. Eur Heart J 1985; 6: 199-211.The MIAMI Trial Research Group: metoprolol in acute myocardial infarction (MIAMI). A randomised placebo controlled international trial. Eur Heart J 1985; 6: 199-211.Herlitz J, Waagstein F, Lindqvist J, et al. Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Goteborg Metoprolol Trial). Am J Cardiol 1997; 80: J40-4.Herlitz J, Waagstein F, Lindqvist J, et al. Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Goteborg Metoprolol Trial). Am J Cardiol 1997; 80: J40-4.ISIS-1 collaborative group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986; 2: 57-66.ISIS-1 collaborative group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986; 2: 57-66.ISIS-1 collaborative group. Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction. Lancet 1988; 1: 921-3.ISIS-1 collaborative group. Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction. Lancet 1988; 1: 921-3.Fibrinolytic Therapy Trialists’ (FTT) collaborative group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-22.Fibrinolytic Therapy Trialists’ (FTT) collaborative group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-22.Owen A. Intravenous beta-blockade in acute myocardial infarction: should be used in combination with thrombolysis. BMJ 1998; 317: 226-7.Owen A. Intravenous beta-blockade in acute myocardial infarction: should be used in combination with thrombolysis. BMJ 1998; 317: 226-7.Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II-B study. Circulation 1991; 83: 422-37.Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II-B study. Circulation 1991; 83: 422-37.Van de Werf F, Janssens L, Brzostek T, et al. Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardiac infarction receiving thrombolytic therapy. JACC 1993; 22: 407-16.Van de Werf F, Janssens L, Brzostek T, et al. Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardiac infarction receiving thrombolytic therapy. JACC 1993; 22: 407-16.Basu S, Senior R, Raval U, et al. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction: a placebo-controlled, randomised trial. Circulation 1997; 96: 183-91.Basu S, Senior R, Raval U, et al. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction: a placebo-controlled, randomised trial. Circulation 1997; 96: 183-91.Pfisterer M, Cox JL, Granger CB, et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. JACC 1998; 32: 634-40.Pfisterer M, Cox JL, Granger CB, et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. JACC 1998; 32: 634-40.Rogers W, Canto J, Lambrew C, et al. Temporal Trends in the Treatment of Over 1.5 Million Patients With Myocardial Infarction in the U.S. from 1990 Through 1999 The National Registry of Myocardial Infarction 1, 2 and 3. JACC 2000; 36: 2056-63.Rogers W, Canto J, Lambrew C, et al. Temporal Trends in the Treatment of Over 1.5 Million Patients With Myocardial Infarction in the U.S. from 1990 Through 1999 The National Registry of Myocardial Infarction 1, 2 and 3. JACC 2000; 36: 2056-63.Gardtman M, Dellborg M, Brunnhage C, et al. Effect of intravenous metoprolol before hospital admission on chest pain in suspected acute myocardial infarction. Am Heart J 1999; 137: 821-9.Gardtman M, Dellborg M, Brunnhage C, et al. Effect of intravenous metoprolol before hospital admission on chest pain in suspected acute myocardial infarction. Am Heart J 1999; 137: 821-9.COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Lancet 2005; 366: 1622-32.COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Lancet 2005; 366: 1622-32.Idle J, Mahdoub A, Lancaster R, et al. Hypotensive response to debrisoquine and hydroxylation phenotipe. Life Sci 1978; 22: 979-83.Idle J, Mahdoub A, Lancaster R, et al. Hypotensive response to debrisoquine and hydroxylation phenotipe. Life Sci 1978; 22: 979-83.Кукес В.Г. Метаболизм лекарственных средств: клинико-фармакологические аспекты. Москва «Реафарм» 2004; 18- 27; 40-7.Кукес В.Г. Метаболизм лекарственных средств: клинико-фармакологические аспекты. Москва «Реафарм» 2004; 18- 27; 40-7.Сычев Д.А., Раменская Г.В., Игнатьев И.В. и др. Клиническая фармакокинетика бета-адреноблокаторов: возможности повышения эффективности и безопасности терапии. Сердце 2006; 3: 162-5.Сычев Д.А., Раменская Г.В., Игнатьев И.В. и др. Клиническая фармакокинетика бета-адреноблокаторов: возможности повышения эффективности и безопасности терапии. Сердце 2006; 3: 162-5.Huang J, Chuang S, Cheng C, et al. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D genotypes. Clin Pharmacol Ther 1999; 65: 402-7.Huang J, Chuang S, Cheng C, et al. Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D genotypes. Clin Pharmacol Ther 1999; 65: 402-7.Kirchheiner J., Heessch C. Bauer S. EImpact of the ultrarapid metabolizer genotype of cytochrome P4502D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 204; 76: 302-12.Kirchheiner J., Heessch C. Bauer S. EImpact of the ultrarapid metabolizer genotype of cytochrome P4502D6 on metoprolol pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 204; 76: 302-12.Koytchev R, Alken R, Vlahov V, et al. Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol. Eur J Clin Pharmacol 1998; 54: 469- 74.Koytchev R, Alken R, Vlahov V, et al. Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol. Eur J Clin Pharmacol 1998; 54: 469- 74.Rau T, Heide R, Bergmann K, et al. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 2002; 12: 465-72.Rau T, Heide R, Bergmann K, et al. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 2002; 12: 465-72.Nozawa T, Taguchi M, Tahara K, et al. Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol. J Cardiovasc Pharmacol 2005; 46: 713-20.Nozawa T, Taguchi M, Tahara K, et al. Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol. J Cardiovasc Pharmacol 2005; 46: 713-20.Wuttke H, Rau T, Heide R, et al. Increased frequency of cytochrome P4502D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002; 72: 429-37.Wuttke H, Rau T, Heide R, et al. Increased frequency of cytochrome P4502D6 poor metabolizers among patients with metoprolol-associated adverse effects. Clin Pharmacol Ther 2002; 72: 429-37.Fux R, Meisner C, Schwab M, et al. Rationale and methods of UNAMET study – a contribution to quality improvement in pharmacotherapy. Z Arztl Fortbild Qual 2004; 98: 689-94.Fux R, Meisner C, Schwab M, et al. Rationale and methods of UNAMET study – a contribution to quality improvement in pharmacotherapy. Z Arztl Fortbild Qual 2004; 98: 689-94.Сычев Д.А., Раменская Г.В., Игнатьев И.В. и др. Влияние генетического полиморфизма в гене цитохрома Р4502D6 на фармакокинетику, фармакодинамику и клиническую эффективность бета-адреноблокатора метопролола у больных хронической сердечной недостаточностью. Мед генетика 2005; 2: 76-81.Сычев Д.А., Раменская Г.В., Игнатьев И.В. и др. Влияние генетического полиморфизма в гене цитохрома Р4502D6 на фармакокинетику, фармакодинамику и клиническую эффективность бета-адреноблокатора метопролола у больных хронической сердечной недостаточностью. Мед генетика 2005; 2: 76-81.

The authors declare that there are no conflicts of interest present.